DIVINCELL SAS.

LOS ANGELES and NIMES, France, May 02, 2024 (GLOBE NEWSWIRE) -- Aanastra, Inc., a biopharmaceutical company focused on developing RNA therapeutics leveraging its peptide delivery technology for targeting cancers and other genetic diseases, today announced multiple presentations at the 2024 American Society for Gene and Cell Therapies (ASGCT), taking place May 7-11, 2024, in Baltimore, MD. ASGCT presentation details are below: Title (Poster): "Peptide Based Nanoparticle-Platform for Extrahepatic Delivery of Functional mRNAs" Session Title: Other Nonviral Delivery Location: Exhibit Hall Abstract Number: 761 Date/Time: Wednesday May 8, 2024, 12:00 PM Presenting Author: DIVITA Gilles, PhD Title (Poster): "Peptide-Based Nanoparticles Mediated mRNA Rescue of Factor VIII; a New Approach to Treat Hemophilia A" Session Title: Liver Genetic Diseases Location: Exhibit Hall Abstract Number: 1093 Date/Time: Thursday May 9, 2024, 12:00 PM Presenting Author: DIVITA Gilles, PhD Title (Poster): "In Vivo CRISPR Mediated Editing of PCSK9 Using Peptide-Based Nanoparticles Durably Lowers Cholesterol in Mice" Session Title: Liver Genetic Diseases Location: Exhibit Hall Abstract Number: 1094 Date/Time: Thursday May 9, 2024, 12:00 PM Presenting Author: DIVITA Gilles, PhD Title (Oral Presentation): "KRAS Mutant Gene Editing Abolishes Tumor Growth In Vivo and Overcomes Acquired Resistance to KRASG12C and KRASG12D Small Molecule Inhibitors" Session Title: Targeted Gene and Cell Therapy II Location: Room 318-323 Abstract Number: 415 Date/Time: Saturday May 11, 2024, 10:15 AM - 12:00 PM Presenting Author: DESAI Neil, PhD More information can be found on the ASGCT meeting website. About Aanastra, Inc. Aanastra Inc (formerly Aadigen Inc) is a start-up biopharmaceutical company focused on treating cancer using its novel RNA therapeutics strategy to target aberrant Tumor Suppressor Genes and Oncogenes. Aanastra’s technology has also been used to target other genetic diseases. The technology driving Aanastra’s approach is based on proprietary RNA combined with proprietary peptides that are able to target various tissues and tumors in vivo unlike commonly used strategies for RNA delivery including viral and lipid-based methods. Aanastra’s strategy for aberrant Tumor Suppressor Rescue using proprietary mRNA and gene editing of mutated Oncogenes have shown remarkable antitumor effects in animal models of various cancers that have mutated P53, KRAS or BRCA1. The utility of Aanastra’s technology has also been demonstrated outside of cancer in animal models of hemophilia A to normalize Factor VIII levels and in cholesterol lowering applications by targeting PCSK9. Aanastra (Los Angeles, CA) works closely with its sister company Divincell SAS (Nimes, France) in the development of its RNA therapeutics. More information on the Company's strategy is available on the Aanastra website at and connect with us on LinkedIn. Contact: IR@aanastra.com

LOS ANGELES and NIMES, France, April 03, 2024 (GLOBE NEWSWIRE) -- Aanastra, Inc., a biopharmaceutical company focused on developing novel RNA therapeutics targeting Tumor Suppressors and Oncogenes, today announced poster presentations at the 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA. AACR poster presentation details are below: Title: " In vivo rescue of p53 tumor suppressor function with ADGN-531 across Pan-p53 alterations "Session Title: Mechanisms of Drug Action Location: Poster Section 26, Board Number 17Abstract Number: 640Date/Time: Sunday Apr 7, 2024 1:30 PM - 5:00 PMPresenting Author: DIVITA Gilles, PhD Title: " Selective deletion of the KRAS mutant gene with ADGN-121 and ADGN-122 peptide-RNA nanoparticles: A new strategy to overcome acquired resistance to KRASG12C and KRASG12D small molecule inhibitors "Session Title: Vector Systems, Oncolytic Virotherapy, and Gene TherapyLocation: Poster Section 27, Board Number 3Abstract Number: 7236Date/Time: Wednesday Apr 10, 2024 9:00 AM - 12:30 PM Presenting Author: DIVITA Gilles, PhD Title: " Peptide-mRNA complex mediated restoration of BRCA-1 tumor suppressor function in BRCA-1 mutated cancers as a new therapeutic strategy "Session Title: Vector Systems, Oncolytic Virotherapy, and Gene TherapyLocation: Poster Section 27, Board Number 4Abstract Number: 7237Date/Time: Wednesday Apr 10, 2024 9:00 AM - 12:30 PM Presenting Author: DIVITA Gilles, PhD More information can be found on the AACR meeting website. About Aanastra, Inc. Aanastra Inc (formerly Aadigen Inc) is a start-up biopharmaceutical company focused on treating cancer using its novel RNA therapeutics strategy to target aberrant Tumor Suppressor Genes and Oncogenes. The technology driving Aadigen’s approach is based on proprietary RNA combined with proprietary peptides that are able to target various tissues and tumors in vivo unlike commonly used strategies for RNA delivery including viral and lipid-based methods. Aanastra’s strategy for aberrant Tumor Suppressor Rescue using proprietary mRNA and gene editing of mutated Oncogenes have shown remarkable antitumor effects in animal models of various cancers that have mutated P53, KRAS or BRCA1. The utility of Aanastra’s technology has also been demonstrated outside of cancer in animal models of hemophilia A to normalize Factor VIII levels and in cholesterol lowering applications by targeting PCSK9. Aanastra (Los Angeles, CA) works closely with its sister company Divincell SAS (Nimes, France) in the development of its RNA therapeutics. More information on the Company's strategy is available on the Aanastra website at www.aanastra.com and connect with us on LinkedIn.